SCI — Investor Presentation 2013

Mar 22, 2013

SCIPHARMTECH, ING.

簡報

ISO 14001 ISO 9001 BUREAU VERITAS BUREAU VERITAS Certification Certification

procedure ThainForm ForwardScon

If HeseoryList.Count > 0 them Foregricket inn, Inshied to Histor

Kat ardAcaion, Enabled is False.

COOL BOUL CORE THE ATTENDANT CONTRACTOR coast pling: Dispatch; var ULL Readily at Gleversence was

ChestoryIndex ++ U) JALES HIRCOLYLIST COUNTY BAY ListoryList Delwie (HistoryL Highlip Ladax in Ristory List. Add

de Riccheylodes := Resinder.
Af Utionsflube than

Portugales is Faire Mei-Teslaw in 1992. KE TAULISSE - PL-ED Uff. j. items, fromest (0, US)

o basi

beals

$end_f$

CANDIDATE REPORT AT TODAY AVE !!

員工數Employee:180 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣493佰萬元(NTD 493mn) 營業項目Business: 原料藥API(40.22%) 中間體Intermediate(48.64%) 特用化學品 Custom-made chemicals(11.14%)

公司概況 Outline

	Y2012	Y2011
歐洲Europe	41.74%	31.17%
美洲America	22.11%	23.97%
亞洲Asia	18.15%	22.32%
國內Taiwan	18.00%	22.54%
合 計Total	100.00%	100.00%

Unit: K NTD

	2012	Jan.-Feb.
營收Sales	1,262,572	202,471
營業成本COGS	(864,684)	(152,970)
毛利Gross Profit	397,888	49,501
毛利率 GP Ratio	31.5%	24.4%
營業費用Operating Expenses	(142,324)	(19,256)
營業利益Operating Income	255,564	30,245
營業外損益Non-Operating In/Ex	(17,410)	(732)
稅前淨利 Net Profit before Tax	238,154	29,513
所得稅Income Tax	(43,705)
稅後淨利Net Profit after Tax	194,449

產品組合-Products

Y2011	%	Y2012	%	Y2013	%	Amount
Di-VaNa	24.51%	V.A.	18.66%	PGA	23.15%	46,864,038
PGA	17.65%	PGA	16.61%	Di-VaNa	15.46%	31,303,398
V.A.	13.76%	Di-VaNa	15.97%	V.A.	10.79%	21,850,371
PPON	10.70%	PPON	7.88%	LPF.Na	7.79%	15,773,694
M85	5.25%	Pent-2	4.78%	PEB.Na	6.46%	13,079,929
Pent-2	3.73%	5-HMT	4.33%	PPON	6.05%	12,251,165
DBS	3.08%	M85	3.89%	DBS	5.25%	10,636,243
M115	2.55%	DBS	2.73%	M85	4.19%	8,484,000
M74	2.31%	M115	2.59%	5-HMT	3.65%	7,399,680
NBE	1.87%	M74	2.18%	NaVa	3.31%	6,696,319
Total	85.40%	Total	79.62%	Total	86.11%

V DEDPM.

SCI PHARMTECH, INC.

$\rightarrow VA$

NaVa

Valproic Acid (VA)

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customers

Propiophenone (PPON)

Sales

第一項產品 First product

15個客戶 15 customers

52,253 47,758 37,509 38,665 60,410 - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2006 2007 2008 2009 2010 2011 2012 Sales Sales

Pent-2

Pentobarbital Sodium

鎮定安眠用之原料藥 API used as calmative

• 2011年開始銷售6佰萬 6mn, starting in 2011. 2012銷售額23佰萬 23mn sales in 2012

第二項產品 Second product 5個客戶 5 customers

4個客戶 4 customers

Hydroxychloroquine

• 2011年開始銷售10.8佰萬 10.8 mn, starting in 2011
• 2012年銷售額33.6佰萬 33.6mn sales in 2012
• 治療風濕性關節炎原料藥(Hydroxychloroquine sulfate) API : Hydroxychloroquine sulfate for rheumarthritis
• 原料藥市場約20噸100 佰萬 API market: 20 MT, 100mn

Anti-inflammatory (Loxoprofen sodium) 2012年銷售5個客戶5佰萬 5 customers, 5 mn sales in 2012. 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg

5-HMT – Ritonavir,Lopinavir

5-Wing– Ritonavir,Lopinavir 2012年開始銷售5.7佰萬 5.7mn, starting in 2012 愛滋病藥物之中間體 For AIDS treatment

產品介紹Product

Antidepressant ( Duloxetine ) 2013年底專利到期 Patent will expire in the end of 2013 2011銷售9.5佰萬予10個客戶 9.5 mn sales consisting of 10 customers in 2011 2012年銷售額8佰萬 8 mn sales in 2012 2011及2012年中間體S-MMAA分別銷售2佰萬及1佰萬 S-MMAA(Intermediate) : 2 mn in 2011, 1mn in 2012. 2010年美國市場製劑銷售值美金31億 USD 3.1 billion in formulation in America in 2010

4-CPE

Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API

SCÏ

SCI PHARMTECH, INC.

歐、日、中國 大陸進口 From abroad

化工分離(蒸餾、萃取、結晶等) Chemical segregations

GMP Status(GMP現況)

API	CGMP certified (TFDA)	CEP (EDQM)	DMF (USA)	MF (Japan)	DMF (Canada)
Valproic Acid	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011
Probucol	2004		2004
Sodium Valproate	2004	2006
Divalproex Sodium	2005		2005		2010
Bisoprolol Fumarate	2006
Pentobarbital Sodium	2009	2011
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011
Duloxetine Hydrochloride	2012		2010/2011
Thiopental acid	2012
Loxoprofen Sodium Hydrate	2012			2011
Clindamycin Palmitate HCl			2011

敬 請 指 教